The One-Year Results of Half-Dose Photodynamic Therapy with Verteporfin in Chronic or Recurrent Central Serous Chorioretinopathy
Pichai Jirarattanasopa MD*, Mansing Ratanasukon MD*, Patama Bhurayanontachai MD*
Affiliation : * Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Objective : To evaluate the one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central
serous chorioretinopathy (CSC).
Material and Method: A Retrospective, consecutive case series. Twenty-seven eyes of 27 patients with chronic symptomatic
CSC or recurrent CSC underwent photodynamic therapy (PDT) with half-dose (3 mg/m2) verteporfin. The demographic data
such as age, side, gender, spot sizes of laser photodynamic therapy (PDT) were recorded. The primary outcomes were the
best correct visual acuity (BCVA), central foveal thickness using the optical coherence tomography (OCT) and complication
were recorded as secondary outcome at baseline, month 1,3,6 and 12 post PDT.
Results : At 12 months after half-dose PDT, the mean logMAR BCVA improved from 0.32 to 0.18 (p = 0.001), the mean central
foveal thickness decreased from 375.52 μm to 186.52 μm (p < 0.001). The results also showed significant improvement of
logMAR BCVA and decreased central foveal thickness after 1 month (0.32 to 0.22, p = 0.003 and 375.52 μm to 175.41 μm,
p < 0.001) and maintained the results until one-year follow-up. Twenty-five eyes (92.59%) showed complete resolution of
subretinal fluid at 1 month, 27 patients (100%) showed complete resolution at 3 month and all sustained the complete
resolution until the last visit. No serious complications were recorded during and after the treatment.
Conclusion : The half-dose PDT in area of fluorescein leakage is one of the effective treatment options for chronic or
recurrent CSC, especially in patients who cannot be performed by focal laser photocoagulation. The treatment sustained the
good visual results and has no serious complications up to one-year.
Keywords : Central serous chorioretinopathy, Half-dose photodynamic therapy, Verteporfin
